Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease
dc.contributor.author | Vickers, Mark A. | |
dc.contributor.author | Wilkie, Gwen M. | |
dc.contributor.author | Robinson, Nicolas | |
dc.contributor.author | Rivera, Nadja | |
dc.contributor.author | Haque, Tanzina | |
dc.contributor.author | Crawford, Dorothy H. | |
dc.contributor.author | Barry, Jacqueline | |
dc.contributor.author | Fraser, Neil | |
dc.contributor.author | Turner, David M. | |
dc.contributor.author | Robertson, Victoria | |
dc.contributor.author | Dyer, Phil | |
dc.contributor.author | Flanagan, Peter | |
dc.contributor.author | Newlands, Helen R. | |
dc.contributor.author | Campbell, John | |
dc.contributor.author | Turner, Marc | |
dc.date.accessioned | 2014-12-12T13:42:01Z | |
dc.date.available | 2014-12-12T13:42:01Z | |
dc.date.issued | 2014-11 | |
dc.identifier | 45030285 | |
dc.identifier | 56bcc831-01e9-4d35-b623-99863d757c5f | |
dc.identifier | 84912035006 | |
dc.identifier.citation | Vickers , M A , Wilkie , G M , Robinson , N , Rivera , N , Haque , T , Crawford , D H , Barry , J , Fraser , N , Turner , D M , Robertson , V , Dyer , P , Flanagan , P , Newlands , H R , Campbell , J & Turner , M 2014 , ' Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease ' , British Journal of Haematology , vol. 167 , no. 3 , pp. 402-410 . https://doi.org/10.1111/bjh.13051 | en |
dc.identifier.issn | 0007-1048 | |
dc.identifier.other | ORCID: /0000-0002-3154-1040/work/76975324 | |
dc.identifier.uri | http://hdl.handle.net/2164/4107 | |
dc.description | Funded by Wellcome Trust Translational Award SNBTS | en |
dc.format.extent | 9 | |
dc.format.extent | 205684 | |
dc.language.iso | eng | |
dc.relation.ispartof | British Journal of Haematology | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject | cell therapy | en |
dc.subject | Epstein-Barr virus | en |
dc.subject | cytotoxicity | en |
dc.subject | lymphoproliferative disease | en |
dc.subject | RC Internal medicine | en |
dc.subject | Wellcome Trust | en |
dc.subject | 102610 | en |
dc.subject.lcc | RC | en |
dc.title | Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease | en |
dc.type | Journal article | en |
dc.contributor.institution | University of Aberdeen.Applied Medicine | en |
dc.description.status | Peer reviewed | en |
dc.identifier.doi | 10.1111/bjh.13051 |